-
Recently, there has been an increased focus on the identification of fetal anomalies and aneuploidy through first and early second trimester maternal testing, which has improved early identification of these disorders.
-
The authors performed a retrospective cohort study of 1,293,423 pregnant women aged 16 to 40 in the United States from June 1, 2005 to May 30, 2008, using data from the Quest Diagnostics Informatics Data Warehouse.
-
-
Sjogren's syndrome is an autoimmune condition that leads to chronic inflammation with salivary and lacrimal gland dysfunction. The diagnosis of Sjogren's often is delayed by several years because the initial presenting symptoms can be non-specific. However, some manifestations of Sjogren's may be life threatening, including brain damage and cancer. It is very important for the primary care physician to recognize the early signs and symptoms and to initiate the appropriate workup and treatment in coordination with consulting specialists to prevent further morbidity and mortality.
-
Previous studies have demonstrated the feasibility of identifying sentinel lymph nodes (SLN) in the pelvic and para-aortic nodal basins in women with endometrial cancer.
-
These authors from Louisiana State University and the University of Hawaii set out to evaluate the quality of information available on the Internet regarding pelvic organ prolapse and urinary incontinence.
-
In this issue: Aspirin and cancer prevention; rivaroxaban for pulmonary embolism; new rhinosinusitis practice guidelines; and FDA actions.
-
Subjects in the Women's Health Initiative (WHI) trial estrogen-only study randomized to receive conjugated estrogens had a lower incidence of invasive breast cancer than did those who received placebo.
-
-
Currently, screening for fetal aneuploidy involves a variety of first-line methods that put into play combinations of maternal serum analytes and ultrasound exams in the first and second trimester, with invasive procedures such as chorionic villus sampling (CVS) and amniocentesis being reserved for those at higher risk by history, age, or worrisome results from first-line screening. As will be discussed, each screening combination comes with its own predictive accuracy and now patients and providers can choose from a buffet of screening options, including going right to the main course (amniocentesis or CVS) if one wants 100% accuracy at a small risk of fetal loss (we quote a 1 in 400 risk with amniocentesis and about a 1 in 100 risk for CVS).
